1. Home
  2. STRO vs DSM Comparison

STRO vs DSM Comparison

Compare STRO & DSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STRO
  • DSM
  • Stock Information
  • Founded
  • STRO 2003
  • DSM 1989
  • Country
  • STRO United States
  • DSM United States
  • Employees
  • STRO N/A
  • DSM N/A
  • Industry
  • STRO Biotechnology: Biological Products (No Diagnostic Substances)
  • DSM Investment Managers
  • Sector
  • STRO Health Care
  • DSM Finance
  • Exchange
  • STRO Nasdaq
  • DSM Nasdaq
  • Market Cap
  • STRO 172.8M
  • DSM 301.0M
  • IPO Year
  • STRO 2018
  • DSM N/A
  • Fundamental
  • Price
  • STRO $1.97
  • DSM $5.77
  • Analyst Decision
  • STRO Strong Buy
  • DSM
  • Analyst Count
  • STRO 7
  • DSM 0
  • Target Price
  • STRO $12.14
  • DSM N/A
  • AVG Volume (30 Days)
  • STRO 1.4M
  • DSM 161.7K
  • Earning Date
  • STRO 11-13-2024
  • DSM 01-01-0001
  • Dividend Yield
  • STRO N/A
  • DSM 3.97%
  • EPS Growth
  • STRO N/A
  • DSM N/A
  • EPS
  • STRO N/A
  • DSM N/A
  • Revenue
  • STRO $160,955,000.00
  • DSM N/A
  • Revenue This Year
  • STRO N/A
  • DSM N/A
  • Revenue Next Year
  • STRO N/A
  • DSM N/A
  • P/E Ratio
  • STRO N/A
  • DSM N/A
  • Revenue Growth
  • STRO 230.90
  • DSM N/A
  • 52 Week Low
  • STRO $1.70
  • DSM $4.69
  • 52 Week High
  • STRO $6.13
  • DSM $6.05
  • Technical
  • Relative Strength Index (RSI)
  • STRO 31.89
  • DSM 28.05
  • Support Level
  • STRO $1.70
  • DSM $5.76
  • Resistance Level
  • STRO $3.01
  • DSM $6.18
  • Average True Range (ATR)
  • STRO 0.20
  • DSM 0.05
  • MACD
  • STRO -0.01
  • DSM -0.03
  • Stochastic Oscillator
  • STRO 20.61
  • DSM 8.33

About STRO Sutro Biopharma Inc.

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

About DSM BNY Mellon Strategic Municipal Bond Fund Inc.

BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.

Share on Social Networks: